Evaluation of short‐term (16‐week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real‐life study on the Chinese population

Real‐life data on guselkumab in psoriasis are limited and not available in China hitherto. This study aimed to evaluate the short‐term effectiveness and safety of guselkumab in patients with psoriasis under Chinese real‐life conditions and to explore the effect of guselkumab on CD4+CD25+Foxp3+ regulatory T cells (Tregs). A Chinese prospective and real‐life study involving patients with psoriasis in Dermatology Hospital of Southern Medical University, Guangzhou, China from April to September 2020 was conducted. A total of 45 patients with psoriasis were finally enrolled in the study. Psoriasis Area Severity Index (PASI) 90 and 100 responses at week 16 were achieved by 88.6% and 45.5% of patients, respectively. The analysis of PASI response in different subgroups showed no statistically significant difference. Univariate logistic regression analysis revealed that at week 16, none of the variables were associated with decreasing PASI 90 response, whereas age at onset of disease was a predictor of PASI 100 response. Dynamic detection of CD4+CD25+Foxp3+ Tregs frequency from peripheral blood suggested a stable maintained trend in terms of guselkumab treatment duration. No severe adverse events occurred during the follow‐up period. This study confirmed the short‐term effectiveness and safety of guselkumab, as well as its good tolerance against psoriasis, in the Chinese population. Guselkumab treatment maintains levels of Tregs in patients with psoriasis.